

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKYC1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 04	Removal of Pre-IPC 8 data fields streamlines displays in USPATFULL, USPAT2, and USPATOLD.
NEWS	3	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS	4	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAPLUS.
NEWS	5	OCT 21	CA/CAPLUS kind code changes for Chinese patents increase consistency, save time
NEWS	6	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS	7	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS	8	NOV 03	New format for Korean patent application numbers in CA/CAPLUS increases consistency, saves time.
NEWS	9	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS	10	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS	11	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS	12	NOV 22	Enjoy a free month of INPADOCDB/INPAFAMDB SDIs!
NEWS	13	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS	14	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS	15	DEC 18	ReaxysFile available on STN
NEWS	16	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS	17	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAPLUS

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,  
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges

and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:52:26 ON 11 JAN 2011

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.23

0.23

FILE 'REGISTRY' ENTERED AT 15:52:44 ON 11 JAN 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JAN 2011 HIGHEST RN 1258930-61-8

DICTIONARY FILE UPDATES: 10 JAN 2011 HIGHEST RN 1258930-61-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.


Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10584485.str



chain nodes :

19 20 21 22 23 24

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 25 26 27 28 29

30

```

chain bonds :
4-19 7-23 10-13 16-24 19-20 20-21 20-22 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-12 10-11 11-12 13-14
13-18 14-15 15-16 16-17 17-18 25-26 25-30 26-27 27-28 28-29 29-30
exact/norm bonds :
4-19 5-7 6-9 7-8 7-23 8-9 8-10 9-12 10-11 11-12 19-20 20-21 20-22
24-25 25-26 25-30 26-27 27-28 28-29 29-30
exact bonds :
10-13 16-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom

```

L1        STRUCTURE UPLOADED

```
=> s l1 sss sam
```

```

SAMPLE SEARCH INITIATED 15:53:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        22 TO ITERATE

```

```

100.0% PROCESSED        22 ITERATIONS        0 ANSWERS
SEARCH TIME: 00.00.01

```

```

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                          BATCH  **COMPLETE**
PROJECTED ITERATIONS:        159 TO        721
PROJECTED ANSWERS:            0 TO        0

```

L2        0 SEA SSS SAM L1

```
=> s l1 sss full
```

```

FULL SEARCH INITIATED 15:53:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -        451 TO ITERATE

```

```


100.0% PROCESSED        451 ITERATIONS        0 ANSWERS
SEARCH TIME: 00.00.01

```

L3        0 SEA SSS FUL L1

```
=>
```

```
Uploading C:\Program Files\Stnexp\Queries\10584485a.str
```



```

chain nodes :
19 20 22 23 24
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 25 26 27 28 29
30
ring/chain nodes :
21
chain bonds :
4-19 7-23 10-13 16-24 19-20 20-21 20-22 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 8-10 9-12 10-11 11-12 13-14
13-18 14-15 15-16 16-17 17-18 25-26 25-30 26-27 27-28 28-29 29-30
exact/norm bonds :
4-19 5-7 6-9 7-8 7-23 8-9 8-10 9-12 10-11 11-12 19-20 20-21 20-22
24-25 25-26 25-30 26-27 27-28 28-29 29-30
exact bonds :
10-13 16-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom

```

L4 STRUCTURE UPLOADED

```

=> s l4 sss full
FULL SEARCH INITIATED 15:55:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 451 TO ITERATE

```

```

100.0% PROCESSED 451 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

```

L5 24 SEA SSS FUL L4

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

395.76

395.99

FILE 'CAPLUS' ENTERED AT 15:56:04 ON 11 JAN 2011  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2011 VOL 154 ISS 3  
FILE LAST UPDATED: 10 Jan 2011 (20110110/ED)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5

L6 5 L5

=> d 1-5 ibib hitstr

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:1192619 CAPLUS

DOCUMENT NUMBER: 151:542808

TITLE: Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry

AUTHOR(S): de Bruijn, Peter; Moghaddam-Helmantel, Inge M. Ghobadi; de Jonge, Maja J. A.; Meyer, Thorsten; Lam, Mei-Ho; Verweij, Jaap; Wiemer, Erik A. C.; Loos, Walter J.

CORPORATE SOURCE: Department of Medical Oncology, Erasmus MC - Daniel den Hoed Cancer Center, University Medical Center, Rotterdam, Neth.

SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2009), 50(5), 977-982  
CODEN: JPBADA; ISSN: 0731-7085

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 784210-87-3, RGB 286638

RL: ANT (Analyte); ANST (Analytical study)

(RGB-286638 in human plasma and urine determined by HPLC-ESI-MS-MS)

RN 784210-87-3 CAPLUS

CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:13464 CAPLUS

DOCUMENT NUMBER: 144:101073

TITLE: therapeutic uses of kinase inhibitors, and compositions thereof

INVENTOR(S): Caligiuri, Maureen G.; Kley, Nikolai A.; Murthi, Krishna K.

PATENT ASSIGNEE(S): GPC Biotech, Inc., USA

SOURCE: PCI Int. Appl., 201 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002119	A2	20060105	WO 2005-US21843	20050617
WO 2006002119	A3	20070222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,  
 KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 CA 2584493 A1 20060105 CA 2005-2584493 20050617  
 EP 1763345 A2 20070321 EP 2005-762859 20050617  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
 HR, LV, MK, YU  
 EP 2027853 A2 20090225 EP 2008-153670 20050617  
 EP 2027853 A3 20110105  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,  
 HR, LV, MK, RS  
 US 20080146555 A1 20080619 US 2007-629638 20071220  
 PRIORITY APPLN. INFO.: US 2004-580868P P 20040618  
 EP 2005-762859 A3 20050617  
 WO 2005-US21843 W 20050617

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 144:101073

IT 784211-90-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (kinase inhibitors for therapeutic use)

RN 784211-90-1 CAPLUS

CN Urea, N-[2,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-  
 piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-  
 morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

IT 784211-55-8 784211-74-1 784211-77-4

784211-81-0 784211-88-7 784211-89-8


784211-91-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (kinase inhibitors for therapeutic use)

RN 784211-55-8 CAPLUS

CN Urea, N-[1,4-dihydro-3-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-


oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 784211-74-1 CAPLUS


CN Urea, N-[1,4-dihydro-4-oxo-3-[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)



RN 784211-77-4 CAPLUS

CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)






● 2 HCl

RN 784211-81-0 CAPLUS


CN Urea, N-[1,4-dihydro-4-oxo-3-[4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 784211-88-7 CAPLUS

CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(4-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:3) (CA INDEX NAME)




●3 HCl

RN 784211-89-8 CAPLUS  
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 784211-91-2 CAPLUS  
 CN Urea, N-[2,4-dihydro-3-[4-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD  
(2 CITINGS)  
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2011 ACS on SIN

ACCESSION NUMBER: 2005:612300 CAPLUS

DOCUMENT NUMBER: 143:109828

TITLE: Inhibitors of cyclin-dependent kinases, compositions  
and uses related thereto

INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur F.; Oalmann, Chris;  
Murthi, Krishna K.; Ram, Siya; Wang, Zhongguo; Huang,  
Jianxing

PATENT ASSIGNEE(S): GPC Biotech, Inc., USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063765	A1	20050714	WO 2004-US43492	20041221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004309415	A1	20050714	AU 2004-309415	20041221
AU 2004309415	B2	20100826		
CA 2551640	A1	20050714	CA 2004-2551640	20041221
EP 1709051	A1	20061011	EP 2004-815554	20041221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,  
BA, HR, IS, YU

CN 1922180	A	20070228	CN 2004-80042035	20041221
CN 100471858	C	20090325		
BR 2004018095	A	20070417	BR 2004-18095	20041221
JP 2007516296	T	20070621	JP 2006-547427	20041221
MX 2006007399	A	20070126	MX 2006-7399	20060623
NO 2006003186	A	20060920	NO 2006-3186	20060710
KR 2006130624	A	20061219	KR 2006-7014820	20060721
IN 2006DN04222	A	20070622	IN 2006-DN4222	20060721
HK 1101399	A1	20091204	HK 2007-109307	20070827
US 20090209530	A1	20090820	US 2009-584485	20090313
US 20100004207	A1	20100107	US 2009-456539	20090618
PRIORITY APPLN. INFO.:			US 2003-531872P	P 20031223
			US 2004-560138P	P 20040406
			US 2004-616480P	P 20041006
			US 2003-460921P	P 20030407
			US 2004-819899	A1 20040406
			WO 2004-US43492	W 20041221

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:109828


IT 784211-55-8	784211-74-1	784211-77-4
784211-81-0	784211-88-7	784211-89-8
784211-90-1	784211-91-2	

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(inhibitors of cyclin-dependent kinases, compns. and uses to modulate  
cell-cycle modulation and control cell growth and differentiation)

RN 784211-55-8 CAPLUS


CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-pyridinyl)-1-  
oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA  
INDEX NAME)



● 2 HCl


RN 784211-74-1 CAPLUS

CN Urea, N-[1,4-dihydro-4-oxo-3-[4-[[4-(2-pyridinyl)-1-  
piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-  
(CA INDEX NAME)



RN 784211-77-4 CAPLUS


CN Urea, N-[1,4-dihydro-3-[[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 784211-81-0 CAPLUS

CN Urea, N-[1,4-dihydro-4-oxo-3-[[4-[[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 784211-88-7 CAPLUS  
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(4-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 784211-89-8 CAPLUS  
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 784211-90-1 CAPLUS  
 CN Urea, N-[2,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 784211-91-2 CAPLUS  
 CN Urea, N-[2,4-dihydro-3-[4-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
(1 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2011 ACS on SIN

ACCESSION NUMBER: 2005:2193 CAPLUS

DOCUMENT NUMBER: 142:51353

TITLE: Pyrazole derivative inhibitors of cyclin-dependent  
kinases for use as antitumor and antiviral agents  
INVENTOR(S): Becker, Frank; Bockovich, Nicholas; Come, Jon H.;  
Kluge, Arthur; Murthi, Krishna K.; Oalman, Chris;  
Ram, Siya; Wang, Zhongguo

PATENT ASSIGNEE(S): GPC Biotech, Inc., USA; GPC Biotech A.-G.

SOURCE: U.S. Pat. Appl. Publ., 103 pp., Cont.-in-part of Appl.  
No. PCT/US02/33052.

CODEN: USXXCO

DOCUMENT TYPE:

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040266854	A1	20041230	US 2004-820453	20040407
US 7605175	B2	20091020		
WO 2002070662	A2	20020912	WO 2002-US6677	20020304
WO 2002070662	A3	20021227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,				
VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030165873	A1	20030904	US 2002-91177	20020304
EP 1975620	A2	20081001	EP 2008-103127	20020304



EP 1975620 A3 20081224  
 R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC,  
 NL, PT, SE, TR, AL, LT, LV, MK, RO, SI  
 US 20040043388 A1 20040304 US 2002-234985 20020903  
 US 7135550 B2 20061114  
 WO 2003033499 A2 20030424 WO 2002-US33052 20021015  
 WO 2003033499 A3 20030814  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 EP 1832589 A1 20070912 EP 2007-8359 20021015  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,  
 LI, LU, MC, NL, PT, SE, SK, TR, AL, LT, LV, MK  
 US 20100004207 A1 20100107 US 2009-456539 20090618  
 PRIORITY APPLN. INFO.: US 2001-272932P P 20010302  
 US 2001-329437P P 20011015  
 US 2001-336962P P 20011203  
 US 2002-91177 A2 20020304  
 WO 2002-US6677 A2 20020304  
 US 2002-234985 A2 20020903  
 WO 2002-US33052 A2 20021015  
 US 2003-460921P P 20030407  
 US 2003-531872P P 20031223  
 US 2001-278233P P 20010323  
 EP 2002-723332 A3 20020304  
 EP 2002-797047 A3 20021015  
 US 2004-819899 A1 20040406  
 ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT  
 OTHER SOURCE(S): CASREACT 142:51353; MARPAT 142:51353  
 IT 784210-87-3P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (pyrazole derivative inhibitors of cyclin-dependent kinases for use as  
 antitumor and antiviral agents)  
 RN 784210-87-3 CAPLUS  
 CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-  
 piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-  
 morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


IT 784211-88-7 784211-89-8 784211-91-2  
 808742-16-7 808742-47-4 808742-55-4  
 808742-63-4

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrazole derivative inhibitors of cyclin-dependent kinases for use as antitumor and antiviral agents)

RN 784211-88-7 CAPLUS

CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(4-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 784211-89-8 CAPLUS


CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-,

hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 784211-91-2 CAPLUS  
 CN Urea, N-[2,4-dihydro-3-[4-[(4-(1-methylethyl)-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2)  
 (CA INDEX NAME)




●2 HCl

RN 808742-16-7 CAPLUS  
 CN Urea, N-[2,4-dihydro-3-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 808742-47-4 CAPLUS  
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-  
 (CA INDEX NAME)




RN 808742-55-4 CAPLUS  
 CN Urea, N-[2,4-dihydro-3-[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 808742-63-4 CAPLUS  
 CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:902355 CAPLUS

DOCUMENT NUMBER: 141:395546

TITLE: Preparation of pyrazole derivatives as inhibitors of cyclin-dependent kinases, compositions and uses related thereto

INVENTOR(S): Bockovich, Nicholas; Kluge, Arthur; Oalman, Chris; Murthi, Krishna K.; Ram, Siya; Wang, Zhongguo; Huang,

PATENT ASSIGNEE(S): Jianxing  
 SOURCE: GPC Biotech, Inc., USA  
 PCT Int. Appl., 172 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092139	A2	20041028	WO 2004-US10381	20040406
WO 2004092139	A3	20050331		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004230867	A1	20041028	AU 2004-230867	20040406
AU 2004230867	B2	20100909		
CA 2521854	A1	20041028	CA 2004-2521854	20040406
US 20040266853	A1	20041230	US 2004-819899	20040406
US 7786112	B2	20100831		
EP 1611136	A2	20060104	EP 2004-759113	20040406
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1798748	A	20060705	CN 2004-80015519	20040406
JP 2006522152	T	20060928	JP 2006-509686	20040406
IN 2005DN05018	A	20070928	IN 2005-DN5018	20051103
NO 2005005195	A	20051104	NO 2005-5195	20051104
US 20100004207	A1	20100107	US 2009-456539	20090618
PRIORITY APPLN. INFO.:			US 2003-460921P	P 20030407
			US 2003-531872P	P 20031223
			US 2004-819899	A1 20040406
			WO 2004-US10381	W 20040406

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 141:395546

IT 784210-88-4P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of pyrazole derivs. as inhibitors of cyclin-dependent kinases)

RN 784210-88-4 CAPLUS

CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl- (CA INDEX NAME)




IT 784210-87-3P 784211-55-8P 784211-74-1P  
 784211-77-4P 784211-81-0P 784211-88-7P  
 784211-89-8P 784211-90-1P 784211-91-2P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (drug candidate; preparation of pyrazole derivs. as inhibitors of  
 cyclin-dependent kinases)  
 RN 784210-87-3 CAPLUS  
 CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-  
 piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-  
 morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 784211-55-8 CAPLUS  
 CN Urea, N-[1,4-dihydro-3-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-  
 oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA  
 INDEX NAME)



● 2 HCl

RN 784211-74-1 CAPLUS


CN Urea, N-[1,4-dihydro-4-oxo-3-[4-[[4-(2-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-  
(CA INDEX NAME)



RN 784211-77-4 CAPLUS

CN Urea, N-[1,4-dihydro-3-[4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)






● 2 HCl

RN 784211-81-0 CAPLUS


CN Urea, N-[1,4-dihydro-4-oxo-3-[4-[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 784211-88-7 CAPLUS


CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(4-pyridinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:3) (CA INDEX NAME)



● 3 HCl

RN 784211-89-8 CAPLUS


CN Urea, N-[2,4-dihydro-4-oxo-3-[4-[[4-(2-pyrimidinyl)-1-piperazinyl]methyl]phenyl]indeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 784211-90-1 CAPLUS


CN Urea, N-[2,4-dihydro-3-[4-[[4-(2-methoxyethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 784211-91-2 CAPLUS

CN Urea, N-[2,4-dihydro-3-[4-[[4-(1-methylethyl)-1-piperazinyl]methyl]phenyl]-4-oxoindeno[1,2-c]pyrazol-5-yl]-N'-4-morpholinyl-, hydrochloride (1:2)  
(CA INDEX NAME)



● 2 HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD  
(5 CITINGS)  
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

(FILE 'HOME' ENTERED AT 15:52:26 ON 11 JAN 2011)

FILE 'REGISTRY' ENTERED AT 15:52:44 ON 11 JAN 2011

L1               STRUCTURE UPLOADED  
L2               0 SEA FILE=REGISTRY SSS SAM L1  
L3               0 SEA FILE=REGISTRY SSS FUL L1  
L4               STRUCTURE UPLOADED  
L5               24 SEA FILE=REGISTRY SSS FUL L4

          FILE 'CAPLUS' ENTERED AT 15:56:04 ON 11 JAN 2011  
L6               5 SEA FILE=CAPLUS SPE=ON ABB=ON PLU=ON L5  
              D 1-5 IBIB HITSTR

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.07	417.06

STN INTERNATIONAL LOGOFF AT 15:56:26 ON 11 JAN 2011